ClinicalTrials.Veeva

Menu

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 4

Conditions

Ocular Hypertension
Glaucoma, Open-Angle

Treatments

Drug: latanoprost 0.005% (Xalatan)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00140062
912-OPT-0091-156

Details and patient eligibility

About

The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension
  • IOP of > 21 mm Hg on current treatment

Exclusion criteria

  • Any previous or current treatment with latanoprost or other prostaglandin analogues

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

27

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems